Monitor for Phase 2 SunStone SLE topline results expected in 4Q 2026, which is the next binary catalyst for obexelimab. The INDIGO open-label extension data incrementally supports the steroid-sparing and flare-protection profile but does not change the near-term regulatory or commercial outlook.
Price Chart
Executive Summary
Zenas BioPharma presented new obexelimab data from the Phase 3 INDIGO open-label extension at the 6th International Symposium on IgG4-Related Disease. The data showed a 12-month probability of remaining flare-free of 0.93, significantly reduced glucocorticoid toxicity vs placebo (GTI score difference -11.4; p=0.021), and vaccine responses during a treatment-free window. The filing is a routine clinical data update with no financial figures or guidance changes.
Key Facts
- 12-month probability of remaining flare-free was 0.93 based on investigator- and adjudication committee-confirmed flares requiring rescue therapy.
- Obexelimab significantly reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI Cumulative Worsening Score difference: -11.4; p=0.021).
- Vaccination during a treatment-free window resulted in seroimmunity to influenza in 6 of 7 (86%) participants and to COVID-19 in 4 of 4 (100%) participants.
- Phase 2 SunStone trial in SLE topline results expected in 4Q 2026.
- No financial data, guidance changes, or material agreements were included in this filing.
Financial Impact
No financial figures reported; clinical data update only.
Risk Factors
- Clinical-stage company with no approved products or revenue.
- Obexelimab requires regulatory approval; Phase 3 INDIGO data is from an open-label extension, not a randomized controlled trial.
- Reliance on single contract manufacturing organization (WuXi Biologics) located in China introduces supply chain and geopolitical risk.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115151 |
| Document: tm2627406d1_8k.htm | 0001104659-26-115151 |
| Document: 0001104659-26-115151-index-headers.html | 0001104659-26-115151 |
| Document: 0001104659-26-115151-index.html | 0001104659-26-115151 |
| Document: 0001104659-26-115151.txt | 0001104659-26-115151 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | Press Release | $26.71 | awaiting T+60 | — | $27.85 (+4.27%) |
Oct 13, 2026 14d ago | 8-K | $25.16 | awaiting T+60 | — | $27.85 (+10.69%) |
Sep 22, 2026 5w ago | Press Release | $33.05 | awaiting T+60 | — | $27.85 (−15.73%) |
Sep 18, 2026 5w ago | Press Release | $32.55 | awaiting T+60 | — | $27.85 (−14.44%) |
Sep 11, 2026 6w ago | S-3ASR | $31.91 | awaiting T+60 | — | $27.85 (−12.72%) |
May 28, 2026 21w ago | Press Release | $18.56 $32.29 | ▲ +73.98% | ▲ +72.24% | $27.85 (+50.05%) |
May 19, 2026 23w ago | Press Release | $17.84 $29.20 | ▲ +63.68% | ▲ +57.39% | $27.85 (+56.11%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.85 (+39.74%) |
May 13, 2026 23w ago | 8-K | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.85 (+39.74%) |
May 13, 2026 23w ago | Press Release | $19.93 $32.43 | ▲ +62.72% | ▲ +58.28% | $27.85 (+39.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers